To compare pregabalin versus placebo and pramipexole for reducing restless legs syndrome (RLS)-related sleep disturbance. Randomized, double-blinded, crossover trial. Twenty-three US sleep centers.
INTRODUCTION
Restless legs syndrome (RLS;; Willis-Ekbom disease) is a impact on daily function and quality of life. [1] [2] [3] For patients with RLS, sleep disturbance is reported as the most common factor affecting quality of life and the main reason for seeking treatment. [4] [5] [6] [7] Development of therapies to address sleep disturbance is thus an important clinical goal.
effective for the improvement of RLS symptoms and reduction of periodic limb movements (PLM). [8] [9] [10] However, rates of PLM in sleep (PLMS) do not correlate strongly with degree of sleep disturbance in RLS 11 on PLMS cannot be assumed to translate to improvements in sleep. Indeed, while polysomnography (PSG) studies have observed trends toward improvement in sleep maintenance with dopamine agonists, improvements in the critical measure [12] [13] [14] [15] [16] [17] [18] [19] [20] Two prior small studies have investigated pregabalin, 2 21, 22 One study demonstrated a dose-dependent reduction in RLS symptoms, and improvements in actigraphy measures of TST and sleep 21 Another demonstrated of sleep maintenance and architecture, and subjective sleep measures, as well as reductions in PLM compared with placebo. 22 cacy of pregabalin for reducing sleep disturbance in moderate to severe RLS was compared with placebo and the dopamine agonist pramipexole.
METHODS
This was a randomized, double-blinded, placebo-controlled, 3-way crossover trial conducted in 23 centers in the United States from December 2009 to June 2011, involving participants with moderate to severe idiopathic RLS with associated sleep Participants meeting screening criteria entered a 14-day single-blind placebo run-in period, with PSG screening on 2 consecutive nights (beginning day 7) to determine eligibility.
sequences, each comprising 3 double-blind treatment periods with pregabalin 300 mg/day, pramipexole 0.5 mg/day, and placebo. Each treatment period included 10 days' dose escalaon 2 consecutive nights (days 28-30). Participants then entered 2 only) ( Figure  1 ).
The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines. The protocol and informed consent documents were approved by the relevant Institutional Review Boards. All participants provided written informed consent. moderate to severe idiopathic RLS 1 with predominantly evening symptoms. At screening, participants were required to have an International RLS Study Group Rating Scale (IRLS) to very severe sleep disturbance secondary to RLS. Participants months and, on screening, met PSG criteria for sleep interfersecondary RLS, sleep/circadian rhythm disorders, conditions that might have confounded assessments (e.g., muscle fascicuin night or shift work, regular napping for > 30 min or regular of > 50% in RLS symptoms during the placebo run-in.
permitted;; stable doses/regimens of medications for chronic conditions were allowed. Medications/substances that may either not permitted (e.g., selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors) or limited (e.g., caffeine, tobacco, alcohol). At least 7 days or > 5 halflives (whichever was greater) was required for washout of prohibited medications prior to the start of single-blind placebo and the screening PSG.
Study medication was dispensed through an interactive voice recognition system according to a randomization code genercapsules of pregabalin (75 mg, 150 mg, and 300 mg), pramipexole 0.125 mg and 0.5 mg, and matching placebos for a triple-dummy design.
Study medication was administered orally once daily, 1 to 3 h before the participant's bedtime (2 h before bedtime during PSG testing). The maintenance dose of pregabalin 300 mg/day 21 The maintenance dose of pramipexole 0.5 mg/day is the maximum recommended for treating RLS in the United States.
23
Pregabalin dosing began at 75 mg/day, with dose escalation to 150 mg/day 0.5 mg/day (day 11). Following each treatment period the drug PSG recordings were performed for an 8-h period in a sleep laboratory and were carried out in accordance with the Rechtschaffen and Kales manual 24 ican Academy of Sleep Medicine 2007 guidelines 25 ). Readings were averaged over 2 consecutive nights. All sleep PSG recordings were evaluated in a blinded fashion by the central laboratory.
minutes the participant was awake after onset of persistent sleep (10 min of non-wake on electroencephalogram);; at the end of each day. At each PSG visit, the Clinical Global Impressions-Improvement (CGI-I) questionnaire, a physician-administered 7-point scale, was completed to assess improvement in RLS compared with the start of study medication. Participants also completed the IRLS 29 and RLS-Quality of Life (QoL) questionnaires, 30 and the Medical Outcomes Study (MOS)-Sleep Scale (SS), 31 with a recall period of the prior week.
-PLMAI, subjective TST (sTST) derived from the SSQ, and
Safety and Tolerability
Safety and tolerability were assessed by monitoring adverse -tory tests, vital signs, concomitant medications, and suicidality. Suicidal ideation and behavior was assessed using the (C-CASA) derived from the Sheehan-Suicidality Tracking Scale (S-STS).
A sample size of 84 participants (14 per treatment sequence) variables (considered as a mean [standard deviation] differ- 25 [70] min for sTST;; 12 [35] min for SWS). Assuming a 20% discontinuation rate, the randomization target was 105 partici--dure to assess for the need to increase the required sample size concluded that no such increase was recommended. Enrollment in the study was stopped, with 85 participants randomized, based on an administrative decision for business reasons a development program and discontinue further investigation of pregabalin in RLS). The observed standard deviation for WASO was 37.5, providing > 99% power with 85 participants intervals (CIs), and treatment group comparisons were estiperiod, and treatment. Participant nested within sequence was included as a random effect. Statistical inferences for treatment group comparisons for the primary and key secondary endpoints were performed using a 2-sided model based t test of LS mean to preserve the experiment-wise type 1 error < 0.05 over the placebo);; (2) PLMAI (pregabalin vs placebo);; (3) sTST (pregabalin vs placebo);; (4) SWS (pregabalin vs pramipexole);; (5) -balin vs placebo). The treatment comparison at each step had to to the next step. Only the endpoints included in the step-down all other assessments, only descriptive statistics are reported (without P values).
RESULTS

Study Population
Approximately equal numbers received each treatment (75 discontinuation rates were broadly comparable across treatments ( Figure 2 ). The mean age of the overall study population was 50.3 to 57.4 years (range across treatment groups) 2.0 to 11.9 years (range across treatment groups). Participant treatment sequences with differences in the ratio of males to from the relatively low numbers of participants per treatment sequence ( Table  1) .
Measures of sleep maintenance improved more with pregabalin than with either placebo or pramipexole ( Table 2) . The primary endpoint, WASO, improved by 27.1 minutes with minutes compared with pramipexole. Sensitivity analyses for the primary endpoint did not indicate any carry-over effect between treatment periods. The key secondary endpoint of compared with placebo and 7.9 awakenings compared with pramipexole (P < 0.0001;; Table  2 ).
The key secondary sleep architecture endpoint of SWS increased by 20.9 minutes with pregabalin compared with placebo and 32.1 min compared with pramipexole (P < 0.0001).
with both pregabalin and pramipexole compared with placebo ( Table  2 ). The frequency of arousals also decreased with pregabalin compared with placebo and pramipexole. Sleep induction, as measured by LPS, was reduced by 7.7 min with pregabalin compared with placebo, which was comparable to the change with pramipexole (Table  2) .
With respect to motor function, the key secondary endpoint of PLMAI improved by 3.7 PLMA/h with pregabalin compared with placebo (P < 0.0001), which was comparable to the improvement with pramipexole. PLMSI also improved with -Participant disposition. AE, adverse event;; ITT, intent-to-treat;; PBO, placebo;; PGB, pregabalin;; PPX, pramipexole. pregabalin compared with placebo;; however, the reduction was less than with pramipexole (Table  2) .
IRLS total score (range, 0-40) improved with pregabalin -pexole (-3.1;; -5.1 to -1.1). A higher proportion of participants also reported that their RLS symptoms were "very much improved" or "much improved" on the CGI-I scale with pregawhile receiving pregabalin (Figure  3) .
Subjective measures of sleep maintenance reported on the SSQ improved with pregabalin compared with placebo and pramipexole (Table 3 ). In particular, the key secondary endpoint of sTST improved by 30.8 min with pregabalin compared with Subjective sleep latency was reduced with pregabalin compared with placebo and was similar to that with pramipexole. The MOS-SS were also improved with pregabalin compared with placebo and pramipexole (Table  4) .
With respect to the impact of RLS on daily living, the key 0-100) also improved with pregabalin compared with placebo a trend towards improvement with pregabalin compared with
Safety and Tolerability
during pramipexole treatment, and 27 (37.0%) during placebo a P values are provided for the primary and key secondary endpoints included in the step-down testing procedure. For other endpoints, only descriptive total sleep time;; WASO, wake after sleep onset.
-Clinical Global Impressions-Improvement. Responders were pramipexole, and 33.3% with placebo). 
Pregabalin Pramipexole Placebo
Patients (%)
Responders Non-responders treatment. The most frequently reported TEAEs during pregabalin treatment were dizziness and somnolence (24.0% and 17.3% of participants, respectively), and during pramipexole treatment were somnolence, headache, and nausea (each in 7.9% of participants;; Table  5 ). Five participants experienced treatment-emergent serious AEs (SAEs). Suicidal ideation in 1 participant, which began on placebo and continued during pramipexole treatment, was considered treatment-related. SAEs of gastroenteritis and hypokalemia during placebo treatment, as well as deep vein thrombosis and decreased blood pressure/postural dizziness during pregabalin treatment, were not considered related to treatpregabalin treatment (3 due to dizziness/balance disorder and 1 hypertension) and 3 during pramipexole treatment (1 due to suicidal ideation, 1 nausea, and 1 agitation). All of these AEs resolved following treatment discontinuation.
DISCUSSION
In this double-blinded, randomized, crossover study, pregabalin 300 mg/day was more effective than placebo and pramipexole 0.5 mg/day in improving sleep disturbance, as assessed by objective and subjective measures of sleep maintenance and sleep architecture, following 4 weeks' doubleblind treatment. Furthermore, pregabalin 300 mg/day improved subjective RLS symptoms (measured by IRLS and CGI-I) more than placebo or pramipexole 0.5 mg/day. The effect of pregabalin on arousals associated with PLM was similar to that of pramipexole, despite smaller overall reductions in PLMS. Pregabalin and pramipexole were generally well tolerated. TEAEs appeared to be more frequent with pregabalin than common TEAEs with pregabalin (dizziness and somnolence) occurring more frequently than the most common TEAEs with pramipexole (nausea, headache, and somnolence).
Improvements in objective measures of sleep were matched by similar improvements in participants' perception of their sleep. For example, subjective and objective reductions in WASO were 25.3 and 27.1 min, respectively, with pregabalin with pramipexole. Pregabalin also improved depth of sleep by increasing SWS and reducing the number of arousals compared with placebo and pramipexole. These results are consistent with PSG data from prior pregabalin trials in patients with RLS, 22 32 and epilepsy, 33 and in healthy volunteers, 34 which similarly demonstrated increases in SWS. An increase 2 and gabapentin enacarbil, suggesting that this may be a class effect. In contrast, prior trials with dopamine agonists have demonstrated decreases in SWS, consistent with results in this study. 15, 17, 18, 20 Of interest for future study would be the effects of pregabalin on sleep microstructure, which has been shown by analysis of cyclic alternating patterns (CAP) to differ between RLS patients and controls.
14 Acute treatment with pramipexole has been shown to fail to correct abnormalities in sleep micro- 14 Overall rates of PLM in sleep were much decreased with pramipexole compared with placebo, with a smaller decrease due to PLM were similar for both drugs. Thus, it seems likely that the effects of pregabalin on sleep in RLS patients are partially independent of improvements in PLM. This apparent disconnect between improvements in motor function and sleep is suggestive of differences in underlying brain function relating to these characteristics of RLS, which may be affected differently by pregabalin (potentially affecting the arousal system) and pramipexole (motor functions). This may also explain the dopamine agonists on PLM and subjective sleep measures, generally been observed. [12] [13] [14] [15] [16] [17] [18] [19] [20] This disconnect between objective sleep measures and the PLM rates and subjective sleep measures with pramipexole could be further evaluated. At the same time, improvements in RLS symptoms, as assessed by IRLS and CGI-I, were greater with pregabalin suggesting that improvement in symptoms correlates better with objective measures of sleep.
Improvements in sleep architecture seen in this study have also been demonstrated in previous placebo-controlled, cross- 2 In these trials, gabapentin was shown to improve TST by approximately 30 minutes (compared with 32.7 min in this study);; however, PLMA/h were 35 In contrast, gabapentin enacarbil was shown to improve PLMA/h (mean treatment difference of -3.1, compared with -3.7 in this study) together with similar improvements in TST (32.7 min) and WASO (28.5 min) to those seen in this study.
A task force recently established by the International RLS of RLS for up to 1 year (with Level A evidence), while pramipexole, ropinirole and rotigotine were established as effective 37 A number of other therpramipexole, and ropinirole (1 year);; levodopa (2 years);; and rotigotine (5 years).
37
The task force recommended either dopa-2 on patient characteristics (e.g., dopamine agonists for patients 2 for patients with severe sleep disturbance or comorbid pain).
In this study, the data suggest that pregabalin may lead to greater improvements in measures of quality of live and subjective sleep than pramipexole. Comparisons of pregabalin with studies of other RLS therapies are challenging due to differences in trial design but ropinirole 38 and rotigotine 39, 40 have also been shown to improve quality of life and subjective sleep. The International RLS Study Group task force indicated that both 2 2 dopamine agonists to improve subjective measures of sleep. 37 Overall, the results of this study, together with prior research, 21, 22 indicate that pregabalin could represent a possible alternative to dopamine agonists for the effective treatment of RLS, and that it may offer greater improvements in sleep maintenance and quality, key clinical treatment goals in RLS. Further investigations should continue to evaluate the relative Short-term AE rates appear to be higher for pregabalin than pramipexole, particularly for dizziness and somnolence, but this may not be the case for AEs over longer-term treatment. In the case of long-term use, dopamine agonists are often limited by the development of augmentation (an increase in the severity of RLS symptoms during treatment), 41 and it would be of interest to determine whether pregabalin, due to its nondopaminergic mechanism of action, is associated with a lower augmentation risk. The design and short duration of the current study did not permit evaluation of effects on augmentation;; however, this could represent another area of future research.
Another limitation of this study was the requirement for a relatively large number of participants to be screened in order to identify 85 participants. This was principally due to the requirement that participants meet the sleep parameter incluminutes on the 2 PSG screening nights (with neither night having WASO < 30 min). This restriction likely also contributed to the lower than expected variance in WASO. Other studies with similar sleep parameter-based inclusion criteria have had similar screening failure rates. 32 While this study was limited to the results could also extend to other patients. This study demonstrated improvements in objective and subjective measures of sleep maintenance and sleep architecture with pregabalin compared with placebo and pramipexole in patients with RLS. Decreases in PLMAI with pregabalin were comparable to those with pramipexole. Pregabalin also improved RLS symptoms compared with placebo and pramipexole.
